CD274 and neoplasm: However, during the clinical development of anti-PD-1/PD-L1 antibodies, tumor PD-L1 expression status was used for patient selection based on the observed association between the objective response rate of anti-PD-1 antibody, pembrolizumab, and tumor PD-L1 expression level (41).